Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661862 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8825946 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL9255423 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL4959388 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8493801 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8493909 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8493183 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8825925 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8494932 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 | |
| SCHEMBL8825949 | 1.00 | LPAR1 (0.51) | LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | claimed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | claimed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | claimed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | claimed |
| EP-0677039-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | claimed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | claimed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | disclosed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | disclosed |
| EP-0677039-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | LPAR1 1046/4885LPAR5 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.